CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new study from St. Jude Children's Research Hospital. Many people with sickle ...
News-Medical.Net on MSN
Breakthrough gene therapy for sickle cell disease remains out of reach in Africa
As Uganda rolls out mandatory nationwide screening of newborns for sickle cell disease this month, a gene therapy celebrated ...
Fifteen-year-old Jayden Wilsey of Falmouth is the first person at Boston Children's Hospital to receive human gene therapy for sickle cell disease, following approval of the therapy in 2024 by the U.S ...
Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new study from St. Jude Children's Research Hospital. Many people with sickle ...
SAN DIEGO — A newly approved gene therapy product for sickle cell disease, lovotibeglogene autotemcel (lovo-cel, marketed as Lyfgenia), led to durable disease remissions for up to 5 years and almost ...
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
Serenity Cole enjoyed Christmas last month relaxing with her family near her St. Louis home, making crafts and visiting friends. It was a contrast to how Cole, 18, spent part of the 2024 holiday ...
Julie Kanter, M.D., (Associate Professor, Hematology and Oncology; Co-director of the UAB Lifespan Comprehensive Sickle Cell Center) and colleagues have been published in the New England Journal of ...
He's the first in New York to receive the novel treatment and one of the first in the world. Share on Facebook (opens in a new window) Share on X (opens in a new window) Share on Reddit (opens in a ...
Delaying onboarding until FDA approval reduces sunk-cost risk but can impede institutional learning and slow post-approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results